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Abstract
The goal of cancer chemotherapy to induce multi-directional apoptosis as targeting a single pathway is unable to decrease
all the downstream effect arises from crosstalk. Present study reports that Withanolide D (WithaD), a steroidal lactone
isolated from Withania somnifera, induced cellular apoptosis in which mitochondria and p53 were intricately involved. In
MOLT-3 and HCT116p53+/+ cells, WithaD induced crosstalk between intrinsic and extrinsic signaling through Bid, whereas
in K562 and HCT116p532/2 cells, only intrinsic pathway was activated where Bid remain unaltered. WithaD showed
pronounced activation of p53 in cancer cells. Moreover, lowered apoptogenic effect of HCT116p532/2 over HCT116p53+/+
established a strong correlation between WithaD-mediated apoptosis and p53. WithaD induced Bax and Bak upregulation
in HCT116p53+/+, whereas increase only Bak expression in HCT116p532/2 cells, which was coordinated with augmented
p53 expression. p53 inhibition substantially reduced Bax level and failed to inhibit Bak upregulation in HCT116p53+/+ cells
confirming p53-dependent Bax and p53-independent Bak activation. Additionally, in HCT116p53+/+ cells, combined loss of
Bax and Bak (HCT116Bax2Bak2) reduced WithaD-induced apoptosis and completely blocked cytochrome c release
whereas single loss of Bax or Bak (HCT116Bax2Bak+/HCT116Bax+Bak2) was only marginally effective after WithaD
treatment. In HCT116p532/2 cells, though Bax translocation to mitochondria was abrogated, Bak oligomerization helped
the cells to release cytochrome c even before the disruption of mitochondrial membrane potential. WithaD also showed in
vitro growth-inhibitory activity against an array of p53 wild type and null cancer cells and K562 xenograft in vivo. Taken
together, WithaD elicited apoptosis in malignant cells through Bax/Bak dependent pathway in p53-wild type cells, whereas
Bak compensated against loss of Bax in p53-null cells.
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Introduction
The primary goal of cancer chemotherapy is to trigger tumor-
selective cell death [1] and the response of tumors to therapy to
undergo cell death mainly depends on how fast tumor cell gets the
signal to accomplish their programmed suicide. In this scenario,
the ideal target of an anti-cancer agent might be mitochondria
because perforation of mitochondrial membrane results in release
of several death-promoting factors which ultimately either caspase
dependently or independently execute cell death [2]. Therefore,
regardless of the pathways involved, it is undoubtedly accepted
that mitochondrial permeabilization is a central event in apoptosis
and is undisputedly regulated by members of Bcl-2 family.
Therefore, in a way, Bcl-2 family members and mitochondria
are important targets of p53 [3]. When p53 encounter cellular
stress, it restricts tumor development by responding to diverse
signals for the ultimate benefit of the organism [4–5]. To achieve
this cellular fate, p53 differentially activate or suppress definite sets
of target genes and for this selection, multiple molecular
mechanisms were involved. For example, p53 sensibly repress
important anti-apoptotic proteins like Bcl-2, Bcl-xl and survivin
whose ultimate outcome was identical to that of the activation of
pro-apoptotic genes [6–8]. Simultaneously, p53 transactivates and
upregulates different pro-apoptotic genes like Bid, Bax, Bak and
Noxa [9–11], which mainly helped in mitochondrial membrane
permeabilization. Besides that, Bid is a pro-apoptotic BH3-only
protein which is cleaved and activated by caspase-8 or truncated
by Granzyme B [12]. This truncated Bid (tBid) then interacts with
Bax or ANT for the permeabilization of mitochondrial membrane
and release cytochrome c along with Smac/DIABLO. Addition-
ally, Bcl-xL has also been shown to inhibit tBid-induced
cytochrome c release [13]. Therefore, Bid plays crucial role by
combining receptor-mediated and mitochondria-mediated path-
ways through cross talk. Hence, chemotherapeutic agents
targeting mitochondrial death are of immense importance,
because this type of agents can enforce death in cells in which
upstream signals normally leading to apoptosis have been disabled.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34277Withanolide D (C4b-C5b,C6b-epoxy-1-oxo-,20b, dihydroxy-
20S,22R-witha-2,24-dienolide; WithaD) is a steroidal lactone
isolated from the leaves of Ashwagandha (Withania somnifera Dunal,
Solanaceae), one of the most reputed medicinal plant of Ayurveda
[14]. The herb forms essential constituent of more than 100
traditional medicine formulations [15–19]. Earlier we have
demonstrated that WithaD effectively induced apoptosis in
leukemia (MOLT-4 and K562) and in primary cells from patients
irrespective of their lineages. Also, we had shown that WithaD-
induced apoptosis was through the early accumulation of ceramide
by the activation of neutral-sphingomyelinase [20]. Here we
wanted to explore the mitochondrial pathway as targeting a single
pathway is unable to decrease all the downstream effect arises from
signal cross talk.
We identified differences in activation pattern of intrinsic and
extrinsic pathways in MOLT-3 and K562 cells, which was
correlated with p53 status as revealed by HCT116p53+/+ and
HCT116p532/2 cells. WithaD robustly enhanced p53 expres-
sion and also induced p53-dependent Bax and independent Bak
upregulation. Additionally, WithaD elicited apoptosis through a
Bax/Bak dependent way in p53-proficient cells, whereas Bak
compensated against loss of Bax in p53-null cells. Moreover,
WithaD induced in vitro growth-inhibitory activity against an array
of p53 wild type (wt) and null cancer cells and inhibits tumor
growth in athymic nude mice. Hence, we suggest that WithaD is a
potent anti-cancer agent that induced mitochondria-mediated
apoptosis both in p53wt and null cells.
Results
WithaD-mediated apoptosis commence through the
involvement of mitochondria
To specify the role of mitochondria in WithaD-induced
apoptosis, we first investigated the expression of pro- and anti-
apoptotic molecules in leukemic cells (MOLT-3 and K562).
Results showed that in both the cells, expression of Bcl-xl and Bcl-
2 were reduced dose dependently after WithaD treatment.
However, in MOLT-3 cells, WithaD showed a prominent increase
in Bax and Bak levels. In contrast, Bax level remains unchanged
after increasing WithaD treatment in K562, whereas Bak was
significantly upregulated (Fig. 1B). These results suggested that in
leukemia, mitochondria related Bcl-2 family proteins were
differentially involved in WithaD-mediated cell death.
To locate the specific death cascade through which WithaD
exerts its action, we investigated the key molecules of intrinsic and
extrinsic pathways. Results showed that WithaD proteolytically
cleaved inactive pro-caspase-9 (47 kDa) after 15 hr of treatment at
0.5 mM dose to form the active 35–37 kDa fragment in MOLT-3.
Moreover, WithaD induced the proteolytic processing of execu-
tioner caspases-7 and -3 and also stimulated a dose-dependent
hydrolysis of the 116 kDa PARP to 85 kDa fragment. In contrast,
in K562 cells, the activation of pro-caspase 9, -7, -3 and PARP
cleavage were only observed at higher concentration of WithaD
(2 mM), suggesting the involvement of intrinsic pathway in both
the cells, only the amount of WithaD required to activate the
pathway was different (Fig. 1C).
Next, we tested the possibility of involvement of extrinsic
pathway in WithaD-mediated apoptosis. In MOLT-3, proteolytic
cleavage of pro-caspase 8 to its active 43 kDa fragment was
observed within 0.5–1 mM WithaD treatment. Moreover, results
showed significant reduction in total Bid expression with increased
dose of WithaD. In contrast, in K562 cells, we did not detect any
active caspase 8 fragments, only the reduced level of pro-caspase 8
was observed. Additionally, Bid level was also remain unaltered
(Fig. 1D). These results suggest that, possibly caspase 9-mediated
intrinsic pathway playing the central role in both the cells in
WithaD-mediated apoptosis.
To confirm the possibility of involvement of intrinsic pathway in
WithaD-induced cell death, we specifically inhibit the caspase -9, -
8 and -3 and measured the apoptosis in MOLT-3 and K562 cells.
Caspase -9 inhibition by LEHD-FMK significantly reduced
WithaD-induced apoptosis both in MOLT-3 and K562, while
caspase-8 inhibition by IETD-FMK only marginally affects
(Fig. 1E). Additionally, caspase-3 inhibition by DEVD-CHO
markedly reduced WithaD-induced apoptosis suggested WithaD-
mediated specific activation of caspase cascade, which ultimately
executed through caspase-3 activation. In summary, these results
confirmed that the contribution of mitochondria-mediated
pathway executed the WithaD induced apoptosis both in
MOLT-3 and K562, although the accomplishment was different.
p53 is a critical mediator of WithaD-induced apoptosis
A consistent difference in the activation of intrinsic and caspase-
8-mediated death receptor pathway in MOLT-3 and K562 cells
along with difference in Bax activation prompted us to find the
reason(s) behind this discrepencie(s). In intrinsic pathway, p53
target crucial subset of Bcl-2 family genes including Bax, Bid, Bcl-
xl etc. [21] or induce the oligomerization of Bak at mitochondrial
level. Therefore, we envisioned that the discrepancies between
MOLT-3 and K562 may be due to the p53 status, as K562 are
p53-null, whereas MOLT-3 is p53 wild type (wt). Therefore, we
next assessed the effect of WithaD on the expression of p53 in
MOLT-3 and K562 along with two other p53 expressing cells
(HCT116 and U87MG). WithaD dose-dependently enhanced p53
expression in MOLT-3, HCT116 and U87MG whereas in K562
there was no p53 expression as expected (Fig. 2A).
Next we used HCT116p53+/+ and a stably p53 knockdown
HCT116p532/2 cells and checked their p53 status (Fig. 2B). We
then investigated the intrinsic and caspase-8 mediated death
receptor pathways in these cells to specifically demonstrate
whether p53 status really made any differences. In
HCT116p53+/+ cells, WithaD induced the activation of cas-
pase-9, caspase-3, caspase-7 and also stimulated the processing of
PARP in similar manner as was observed in MOLT-3.
Interestingly, activation of caspase-9 was only occurred at higher
dose and caspase-3, caspase-7 and PARP cleavage proceed
subsequently in HCT116p532/2 cells as was in K562 (Fig. 2C).
In case of caspase-8-mediated death receptor pathway, active
caspase-8 fragment was formed at 2.0 mM in HCT116p53+/+
cells, while in HCT116p532/2 cells, only the level of pro-
caspase-8 was reduced. Additionally, reduction of total Bid
expression was observed merely in the highest dose in
116p532/2 cells (Fig. 2D). Therefore, these results suggested
that disparities in the activation of intrinsic and extrinsic pathway
might be due to the variation in p53 status.
Next, we evaluated whether presence of p53 really made a
difference in WithaD-induced apoptosis. Results showed that only
26.1% HCT116p53+/+ cells were viable at 24 hr at 5 mM dose
whereas at identical conditions 43.8% HCT116p532/2 cells were
viable (Figure S1). Similar differences were observed after 48 hr of
WithaD treatment. Moreover, this trend of differences i.e. lower cell
death in HCT116p532/2 compared to HCT116p53+/+ were
also observed in annexinV-PI staining (Fig. 2E) which was further
reflected in the changes of cell morphology (Fig. 2F). With
increasing dose of WithaD, HCT116p53+/+ cells lost their
adherent property, detached from the substratum and also rounded
up. In contrast, HCT116p532/2 cells showed more adherences to
its niche with extended normal cellular morphology. These results
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apoptosis.
WithaD induced p53-dependent Bax and p53-
independent Bak activation
Having established that p53 is a crucial mediator and
mitochondria playing important role in WithaD-induced apopto-
sis, we next attempt to find the missing link between these two
events. Hence, efforts were made to identify the role of different
p53 downstream effector molecules related to mitochondrial
apoptosis along with Bcl-2. Results showed that in
HCT116p532/2 and HCT116p53+/+ cells, expression of Bcl-
xl and Bcl-2 were reduced dose dependently after WithaD
treatment. Being a p53 target molecule, Bcl-xl’s reduction
irrespective of p53 status could be explained by the fact that
there may be other factors regulating Bcl-xl. Also, an increase in
p21 level was observed in both the cells. However, WithaD
showed a prominent dose-dependent increase in Bax and Bak
levels in constitutive p53 expressing cells. In contrast, in p53-null
cells, Bax level remains unchanged even at higher doses as was
observed in K562, whereas under identical conditions Bak was
significantly upregulated (Fig. 3A). These results suggested that
possibly Bax was upregulated p53 dependently, while Bak
upregulation was p53 independent. To scrutinized the p53
dependency of Bax, we specifically inhibited p53 expression with
pifithrin-a in HCT116p53+/+ cells. A significant reduction of Bax
expression was observed, while Pifithrin-a failed to affect the
enhancement of Bak expression confirming p53-dependent Bax
and p53-independent Bak activation (Fig. 3B).
Bak functionally harmonizes for Bax in p53-null cells to
release cytochrome c
To this end, we have established comparable different time scan
for transmitting the intrinsic apoptotic signal and differential
upregulation of Bax and Bak in p53 wt and null cells. These
prompted us to further define the role of Bax and Bak in WithaD-
induced mitochondrial apoptosis. Therefore, we further investi-
gated Bax and cytochrome c level in both mitochondria and
Figure 1. WithaD-induced apoptosis occurs mainly through intrinsic pathway. (A) Chemical structure of WithaD isolated from leaves of
Withania somnifera. MOLT-3 and K562 cells were treated with (0–4 mM) WithaD for 15 hr and subsequently evaluated for the (B) expression of pro-
survival (Bcl-xl, Bcl-2) and pro-apoptotic (Bak, Bax) Bcl-2 family members; (C) proteolytic processing of pro-caspase-9, -3 and -7 and the cleavage of
PARP and (D) activation of caspase-8 and reduction of total Bid. In each experiment, b-actin served as the loading control. (E) For blocking assay,
MOLT-3 and K562 cells were pre-incubated with or without IETD-FMK (20 mM), LEHD-FMK (20 mM) and DEVD-CHO (100 mM) for 1 hr followed by
incubation for an additional 48 hr in presence of WithaD (2 mM) and % of apoptotic cells (annexinV+/PI+) were measured by flow cytometry.
‘*’ indicates the difference was statistically significant (P,0.005) in WithaD+z-LEHD-FMK and WithaD treated cells.
doi:10.1371/journal.pone.0034277.g001
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Release of cytochrome c in cytosol was enhanced along with
decrease in Bax level in cytosolic fraction of HCT116 p53+/+
cells. In mitochondrial fraction, we observed significant accumu-
lation of Bax and reduced cytochrome c level. Interestingly, we
observed WithaD-induced dose-dependent oligomerization of Bak
in mitochondria (Fig 4A). Initially at lower dose (0.5 mM), the level
of monomeric (16) and oligomerized (26 and 36) Bak were
minimal. Consequently, generation of 16,2 6and 36oligomeric
Bak were enhanced as we have increased the dose of WithaD to 1–
2 mM. However, at higher doses (3–4 mM), significant production
of 36oligomeric Bak and concurrently reduction of 16and 26
form was observed.
In HCT116 p532/2 cells, cytochrome c level was enhanced in
cytosolic fraction although Bax level remains unaltered. However,
in mitochondrial fraction only basal level of Bax and reduced
cytochrome c level was observed. Interestyingly, in HCTp532/2
cells a robust upregulation and generation of oligomeric Bak (36)
Figure 2. p53 is crucial in WithaD-induced apoptosis. (A) Cells were treated with WithaD (0–4 mM) for 15 hr and p53 expression was evaluated
in the lysate of MOLT-3, HCT116, U87MG and K562 cells by Immunoblot. (B) Status of p53 in HCT116 p53+/+ and stably knockdown HCT116p532/2
cells. (C) WithaD (0–4 mM) treatment led to proteolytic processing of pro-caspase-9, -3 and -7 and the cleavage of PARP as determined by
immunoblot analysis after 15 hr in HCT116p53+/+ and HCT116p532/2 cells. (D) Effect of WithaD (0–4 mM) on activation of caspase-8 and reduction
of total Bid after 15 hr of treatment in HCT116 p53+/+ and HCT116p532/2 cells. In each immunoblot, b-actin was served as the loading control. (E)
Difference in WithaD (0–4 mM) mediated apoptosis induction in HCT116 p53+/+ and HCT116p532/2 cells for 24 hr. (F) Morphological changes as
evaluated by phase contrast microscopy in HCT116 p53+/+ and HCT116p532/2 cells after 24 hr WithaD (2 and 4 mM) treatment.
doi:10.1371/journal.pone.0034277.g002
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e34277Figure 3. WithaD induced p53-dependent Bax and p53-independent Bak activation. (A) Expression of p53 downstream effector molecules
including Bcl-xl, Bcl-2, p21, Bak and Bax were evaluated by immunoblot assay after WithaD (0–4 mM) for 15 hr in HCT116p53+/+ and HCT116p532/2
cells. (B) HCT116p53+/+ cells were pre-incubated with pifithrin a (30 mM) for 1 hr followed by 15 hr WithaD (0–2 mM) treatment and the protein level
of p53, Bax and Bak were evaluated by Western blot. In each blot, b-actin served as the loading control.
doi:10.1371/journal.pone.0034277.g003
Figure 4. Cytochrome c was released before mitochondrial depolarization. (A) To detect cytochrome c release, cytosolic and mitochondrial
fraction of HCT116p53+/+ and HCT116p532/2 cells were separated as mentioned in materials and methods and electrophoresed on 15% SDS-PAGE
and immunoblotted using anti-cytochrome c antibody. Cytosolic Bax and cytochrome c were evaluated by Western blot analysis and b-actin served
as the loading control. Mitochondrial Bak oligomerization, Bax and cytochrome c were detected by Western blot and Cox IV served as mitochondrial
loading control. (B) Mean fluorescence intensity (MFI) of FL1 was evaluated in HCT116p53+/+ and HCT116p532/2 after JC1 staining. Dose
dependent treatment of WithaD (0–4 mM) revealed no significant changes in MFI value at15 hr. # considered not significant difference (P=0.125)
between untreated and WithaD (3 mM) treated cells.
doi:10.1371/journal.pone.0034277.g004
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compared to HCT p53+/+ cells. These results suggested that both
Bax and Bak were involved in cytochrome c release to activate
intrinsic pathway in p53 wt cells, while only Bak was responsible
for the same.
Cytochrome c release and mitochondrial membrane depolar-
ization are two important events in intrinsic pathway mediated
apoptosis. These two events are differentially regulated and
induction of cytochrome c release is either dependent or
independent on the detectable loss of the negative electrical
gradient across the mitochondrial membrane [22]. Hence, we
tested the possibility whether WithaD-induced cytochrome c
release was through Bax and/Bak or due to mitochondrial
membrane depolarization (Fig. 4B). We observed no detectable
change in the MFI value of green fluorescence upto 2 mM,
whereas even at 0.5 mM considerable release of cytochrome c in
cyotsol was detected in both the cells. However, mitochondrial
membrane potential loss may also be resulted due to the
generation of ROS into the mitochondrial lumen. A recent study
reports that production of ROS in mitochondria requires Bak in a
Bax-independent manner. Additionally, the activation of Bak
responsible for ROS production is dependent on the cytosolic
presence of tBid [23]. Interestingly, although WithaD activated
Bak, it was unable to produce early ROS either dose or time
dependant manner (Figure S2). Therefore, it may be suggested
that Bax and/Bak are responsible for cytochrome c release in
cytosol rather than mitochondrial membrane depolarization.
To further delineate the role of Bax and Bak in WithaD-
induced cell death, we took HCT116p53+/+ cells either wild
type (HCT116Bax+) or homozygously deleted for the bax
(HCT116Bax2) generating four sublines HCT116Bax+/Bak+,
HCT116 Bax2/Bak+,H C T 1 1 6 B a x +/Bak2 and HCT116Bax2/
Bak2. Results showed p53 level enhanced dose dependently in all
the cells and also Bax and Bak expression satisfy their sub-cell line
status (Fig. 5A). Most importantly, WithaD dose dependently
augmented the level of cytochrome c in cytosol in HCT116 Bax+/
Bak+ whereas totally abolished the cytochrome c release from
mitochondria in HCT116Bax2/Bak2 cells having complete loss of
Bax and Bak. Interestingly, single lossof Bax or Bak could release the
cytochrome c in HCT116 Bax2/Bak+ and HCT116 Bax+/Bak2,
only the intensity was lower than that of HCT116 Bax+/Bak+ cells.
Next, we wanted to explore the role of Bax and Bak with
WithaD-mediated mitochondrial apoptosis. Hence using all four
cell lines, we determined the cellular viability and results showed
that after 24 hr of WithaD (2 mM) treatment, HCT116Bax2/
Bak2 showed 68.12% viability, whereas HCT116Bax+/Bak+
showed only 42.65%. Interestingly, in HCT116 Bax2/Bak+ or
HCT116Bax+/Bak2 viabilities were 55.02 and 59.11% respec-
tively (Fig. 5B). Similar trend was observed in 48 hr viability
(Fig. 5C) and 7-AAD staining assays (Fig. 5D). These results
suggested that WithaD elicited apoptosis through Bax/Bak
dependent way in p53-functional cells, whereas in Bak dependent
way in p53-null cells as was observed in K562.
WithaD inhibited in vitro and in vivo tumor growth in
nude mice model
To check the contribution of p53 in WithaD-induced cell death,
we have used a few p53wt (SiHa, HCT116, U87MG) cell lines
along with MOLT-3 and p53-null (K562, H1299) cells of different
cancer origins. Continuous exposure of different doses of WithaD
for 24 and 48 hr revealed dose-dependent growth inhibition of
p53wt cells, IC50 values being 0.75 mM, 0.9 mM, 0.75 mM and
1.0 mM for MOLT-3, HCT116, U87MG and SiHa respectively
after 48 hr, whereas in p53-null cells reduction of cell growth was
lower for K562 [19] and H1299 than that of the p53wt cells
(Figure S3). This discrimination in sensitivity of p53wt and null
cells were also reflected by the total disintegration of cell
morphology and reduced cell density. Flow cytometric study
revealed significant increase in numbers of annexinV-positive and
both annexinV-PI- positive (Figure S4) cells in all the cancer cells
indicating higher apoptosis in p53wt cells.
We have also examined the in vivo efficacy of WithaD against
K562 xenograft in athymic nude mice. Tumor growth inhibition
was most evident in mice treated with WithaD at 10 mg/kg/day,
where ,80% reduction in tumor size was observed, in contrast
with mice treated with vehicle (Fig. 6A). The average body weights
of the control and WithaD-treated mice did not differ significantly
throughout the study (data not shown). Moreover, the WithaD-
treated mice seemed healthy and did not exhibit signs of distress
such as impaired movement or posture and indigestion. The
average tumor volume in WithaD-treated mice was significantly
lower compared with control mice on every day of tumor
measurement (Fig. 6B). For example, on 6th day, the average
tumor volume in control mice (1,080 mm
3) was ,5 fold higher
compared with WithaD-treated mice (200 mm
3). Consistent with
tumor volume data, the average weight of the wet tumor was
significantly lower in WithaD-treated mice compared with control
mice (data not shown). To test whether WithaD-mediated
inhibition of K562 xenograft growth in vivo was associated with
reduced cell proliferation and/or increased cell death, tumor
tissues from control and WithaD-treated mice were processed for
PI positivity. Data from a representative mouse of each group were
shown in Fig. 6C. The tumor cells from the WithaD-treated mice
exhibited a significantly higher PI positivity compared with control
tumors. Collectively, these results indicated that WithaD admin-
istration caused suppression of cellular proliferation and increased
cellular death in the tumor. The histological data indicated that
the minimal toxic effects over non-specific tissues (section of lungs,
liver and spleen) of WithaD-treated nude mice. Results showed
almost no toxic patches in the histological sections of spleen and
lungs (Fig. 6D) after WithaD treatment. Only the liver was
underwent some stress condition, which was identified by less
packed density of the liver cells. Thus, WithaD administration
significantly inhibited K562 xenograft growth in female nude mice
minimally affecting the normal tissue.
Discussion
The discovery of anti-leukemic activity and a novel ceramide
signaling of WithaD encouraged us to explore its ability as a multi-
signal inducing anti-cancer agent and decipher the molecular
mechanism of this natural product. Accordingly, the major
findings of the present investigation in WithaD-induced cell death
include (a) involvement of mitochondrial pathway, (b) p53 as
critical mediator, (c) role of Bak and Bax in p53-null and wt cells
and (d) demonstration of in vitro and in vivo growth-inhibitiory
activity of WithaD fulfilling the criteria of a potent multi-faceted
anti-cancer agent.
Apoptosis can be triggered through multiple signaling pathways,
but the ultimate event by which physiological or chemotherapy
induced cell death occurred is permeabilization of mitochondrial
membrane. This ‘point-of-no-return’ in the cell death machinery is
a complicated process and regulated mainly by the anti- and pro-
apoptotic members of Bcl-2 family proteins. Hence the exploration
of the role of Bcl-2 family members after WithaD treatment
revealed significant upregulation of both Bax and Bak in MOLT-3
but Bak was upregulated only in K562, while Bcl-2 and Bcl-xl was
downregulated in both the cells. Additionally, activation of
WithaD Induced Bax and/or Bak Dependent Apoptosis
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and dose dependent decrease of total Bid clearly indicated the
activation of both intrinsic and extrinsic signaling in WithaD-
mediated apoptosis in MOLT-3. In contrast, in K562 cells
absence of early proteolytic processing of pro-caspase-8 and almost
unchanged total Bid expression indicated towards the inactivation
of death receptor signaling. Therefore, intrinsic pathway plays the
central role in WithaD-mediated apoptosis in both the cells.
Moreover, significant reduction in apoptogenic effect of WithaD
after inhibition of caspase 9 further confirmed that WithaD-
induced cell death commence mainly through mitochondrial
pathway. However, a consistent difference exists in the com-
mencement of intrinsic and caspase-8-mediated death receptor
pathways in MOLT-3 and K562 cells. K562 being p53-null cell
hinted us about the role of p53 in WithaD-induced cell death. p53
is not just a tumor suppressor protein that singly decide cells’ fate,
instead it is a central component which intricate network of signals
and molecular interactions [24]. It has the ability to activate both
the extrinsic and intrinsic apoptotic pathways. Extrinsic pathway is
activated through the induction of Fas, DR5 and PERP [25–26]
whereas in case of intrinsic pathway, p53 target Bcl-2 family
proteins at mitochondrial level thus ultimately releasing cyto-
chrome c [27].
WithaD have been shown to induce robust upregulation of p53
in MOLT-3 and two other cancer cells including HCT116 and
U87MG having functional wild type p53. To exclude the
variations in results due to different cell lines (MOLT-3 and
K562) and to evaluate the role of p53 in WithaD-induced
apoptosis, we used HCT116p53+/+ and HCT116p532/2 cells.
Here we identified similar activation of intrinsic and death
receptor signaling in HCT116p53+/+ cells as was in MOLT-3.
Bid is a unique protein, playing the crucial role of maintaining the
flow of death signal from cell surface to mitochondria. Activation
of Bid mainly depends on either truncation by activated caspase 8
or transcriptional regulation by p53 [28]. Activated Bid then
translocates to mitochondria and activates Bax and Bak to initiate
intrinsic signal leading to apoptosome formation. Hence, p53
appears to promote the convergence of intrinsic and extrinsic
pathways through Bid regulation [29]. Dose dependent decrease
of total Bid in HCT116p53+/+ cells thereby clearly suggests that
functional p53 simultaneously activate both intrinsic as well as
extrinsic pathways intimated through Bid after WithaD treatment.
Strikingly, in HCT116p532/2 cells, early processing of pro-
caspase-8 was totally absent, although activation of caspase 9, -3,
-7 and cleavage of PARP was observed. Moreover, almost
unchanged Bid expression indicated towards the inactivation of
Figure 5. Bax and Bak were critical mediator of WithaD-mediated apoptosis. (A) Expression of p53, Bax, Bak and Cytochrome c were
evaluated in the lysate of HCT116 cells proficient for Bax and Bak (Bax+/Bak+), deficient for either Bax (Bax2/Bak+) or Bak (Bax+/Bak2) or deficient for
both Bax and Bak (Bax2/Bak2) after WithaD (0–2 mM) treatment for 15 hr by Western blot analysis. Each sub-lines were treated with WithaD (0–
4 mM) for (B) 24 and (C) 48 hr and viabilities were determined by MTT assay. (D) Apoptosis induction was assessed by flow cytometric detection of
each sub-lines by 7-AAD staining. ‘*’ indicates the difference was statistically significant (P,0.005) between HCT116Bax+/Bak+ and HCT116Bax2/
Bak2 cells.
doi:10.1371/journal.pone.0034277.g005
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receptor Fas (CD95/Apo-1) is a key component and in turn
promotes cell death through caspase-8 [30]. However, Fas appears
to be dispensable for p53-dependent apoptosis [31]. Therefore, the
plausible explanation of the abrogation of extrinsic pathway is due
to the absence of p53 in HCT116p532/2 as well as in K562.
Furthermore, reduced sensitivity of p53-null (HCT116p532/2)
than p53wt (HCT116p53+/+) cells towards the apoptogenic effect
of WithaD suggested a crucial role of p53 in WithaD-mediated
apoptosis.
During the induction of mitochondrial apoptosis by a death
stimulus, the role of p53 is manifold and therefore considerably
difficult to follow [5]. p53 can target itself to the mitochondrial
compartment or transactivate or trans-repress specific genes
rendering its effect of mitochondrial death [4,6]. Among them,
Bak and Bax play the pivotal role of gatekeepers of mitochondrial
integrity and cytochrome c release [32]. After WithaD treatment,
significant upregulation of both Bax and Bak in HCT116 p53+/+
cells but upregulated Bak only in HCT116p532/2 cells suggested
p53-independent Bak activation. Inhibition of p53 substantially
reduced Bax but not Bak in HCT116 p53+/+ cells further
confirming p53-dependent Bax and independent Bak activation.
Therefore, activation of mitochondrial pathway in p53-null cells
could be explained through the differential upregulation of Bax
and Bak which is well correlated with p53 status.
Bax and Bak both can be activated either p53 dependently or
independently. p53 can bind directly to Bak and induce a
conformational change in the N-terminus encouraging the
oligomerization thus allowing the release of cytochrome c and
other pro-apoptotic proteins [27]. Similar function of p53 with
Bax was also evident [33]. Alternatively, Degenhardt et al reported
p53 independent role of Bax and Bak in tumor suppression [34].
Bax and Bak are also reported to have necessary function in
staurosporin, UV radiation, etoposide, thapsigargin, and tunica-
mycin-induced apoptosis [31]. Here, reduced apoptosis in
HCT116Bax2Bak2 cells over HCT116Bax+Bak+ cells and
marginal effect of single loss of Bax or Bak on the cell death
clearly suggests that Bak can functionally complement for the loss
of Bax and vice versa. Therefore when both Bax and Bak were
present, WithaD-induced mitochondrial apoptosis was most
potent as was observed in MOLT-3. In agreement with differential
role of Bax and Bak, Bax translocation along with Bak
oligomerization revealed perfect coordination with cytochrome c
release in HCT116 p53+/+ cells. In striking contrast, no Bax
translocation was found in mitochondria of HCT116p532/2
cells, although release of cytochrome c did not differ from
HCT116 p53+/+ cells. A robust Bak upregulation and oligomer-
ization further indicates toward the fact that in HCT116p532/2
cells, WithaD triggered mitochondrial apoptotic pathway that
predominantly depends on Bak but not Bax. Loss of DYm only at
Figure 6. WithaD inhibit in vitro and in vivo K562 xenograft growth. (A) WithaD could prolong the survival time of nude mice injected with
K562. The tumor load of treated mice (10 mg/kg body weight) was visibly lower than untreated control mice. (B) WithaD significantly reduced tumor
volume. Each point represents mean of three tumors. (C) Status of PI-positive cells in untreated and WithaD-treated tumor cells. PI-positive cells (&)
were determined with respect to PI unstained cells (%). (D) Tissue section of spleen, lungs and liver of nude mice (control and WithaD treated)
determined by H&E staining and observed both in 206and 406.
doi:10.1371/journal.pone.0034277.g006
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earlier event than mitochondrial DYm dissipation where Bax
and/or Bak were solely responsible for that.
In conclusion, WithaD elicited mitochondria-mediated apopto-
sis in malignant cells through a Bax/Bak dependent way in p53wt
cells, whereas Bak compensated against loss of Bax in p53-null
cells (Fig. 7). Hence, although extrinsic pathway and Bax were
crippled due to absence of crucial p53, WithaD is able to recruit
Bak which p53-independently can induce apoptosis in p53-null
cells. Therefore, this study highlights a new possibility of using
WithaD as alternative anti-cancer agent along with the existing
chemotherapeutic agent which potentially target mitochondria-
mediated apoptosis both in p53wt as well as p53-null malignant
cells.
Materials and Methods
Reagents
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) was purchased from Sigma (St Louis, MO). The antibodies
against p53, cytochrome c, caspase-3, FITC-annexin V, propi-
dium iodide (PI), annexin V binding buffer, 7-AAD, BD
Mitoscreen kit (JC 1) were from BD Bioscience (San Diego,
USA). Antibodies against PARP, Bax, Bak, Bcl-2, Bcl-xl, Bid, p21,
caspase 7, caspase-8, caspase-9 and HRP-secondary antibodies
were from Cell Signaling Technology (USA). Cocktail protease
inhibitor, z-VAD-fmk, z-IETD-fmk z-LEHD-fmk, z-DEVD-CHO
were from Calbiochem. RPMI-1640, IMDM and fetal bovine
serum (FBS) were from Gibco/BRL, USA.
Withanolide D
WithaD (M.W 470.6) was purified in high yields from the leaves
of a well known medicinal plant Withania somnifera as described
previously [35]. The pure compound was crystallized and
analyzed by IR, mass,
1HNMR and
13C-NMR spectral analysis.
The chemical structure of WithaD has been characterized as C28
steroidal lactone, namely C4b-hydroxyC5b,C6b-epoxy-1-oxo-
,C20b,dihydroxy-20S,22R-witha-2,24-dienolide (Fig. 1A). WithaD
was dissolved in absolute ethanol as 0.5 mM solution and stored at
270uC.
Cell lines and culture conditions
Chronic myelogenous leukemia (K562), colorectal carcinoma
(HCT116), cervical carcinoma (SiHa), brain carcinoma (U87MG)
and lung carcinoma (H1299) cells were purchased from ATCC.
K562 cells were cultured inRPMI-1640 mediumand restof the cells
were cultured in IMDM supplemented with 10% FBS and
incubated in 5% CO2-95% air humidified atmosphere at 37uC.
HCT116p532/2 cells were kindly provided by Dr. S. Roychowdh-
ury (CSIR-IICB). HCT116Bax2/Bak2 and HCT116Bax+/Bak2
cell lines were a kind gift from Prof. G. Chinnadurai, Institute for
Molecular Virology, USA. HCT116Bax2/Bak+ cells were a
generous gift from Dr B. Vogelstein, Johns Hopkins University,
USA.AlltheseHCT116sub-celllineswereculturedaccordingtothe
originator [9].
Viability assay by MTT
Cells (1610
4/250 ml/well) in log phase were seeded on 96-well
tissue culture plates incubated with WithaD (0–5 mM) for 24 and
48 hr at 37uC. After incubation, MTT (0.1 mg/well) was added,
Figure 7. Probable mechanism of WithaD induced apoptosis. WithaD treatment induces p53 activation and mitochondrial apoptosis in
p53wt cells in Bax and Bak dependent manner. However, in p53-deficient cells, lack of Bax function is complemented with Bak in WithaD-induced
mitochondrial apoptosis.
doi:10.1371/journal.pone.0034277.g007
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resultant pellet was dissolved in DMSO. Absorbance of the
resultant formazon was measured at 550 nm using a plate reader
(Multiskan Ex, Thermo Electron Corporation).
Tumor xenograft study
Female nude mice of 6–7 weeks, having 20–22 gm of body
weight were acclimated for 1 week in pathogen free condition. For
subcutaneous xenograft study, mice were randomized in two
groups; control and experimental, each group containing 5 mice.
Exponentially growing K562 cells were suspended in 1:1 RPMI-
matrigel (BD bioscience) and 0.2 ml suspension containing 1610
7
cells were injected s.c. on right flank of each mouse above the hind
limb of each mice [36]. Tumor was allowed to develop for 20–25
days and tumor volumes were recorded till it reached 100–
120 mm
3. The mice were then injected i.p. with either vehicle
(10% DMSO, 0.15 M NaCl) or vehicle containing 10 mg
WithaD/Kg body weight per day for subsequent 8 days. Tumor
volume was measured in a regular basis by external caliper and
calculated as follows: L6W
2/2 (mm
3); where L=length,
W=width. On the 9
th day, mice were sacrificed and tumor
xenografts were excised from each mouse. By collagenase type II-
DNase I treatment, the tumor cells were isolated from tumor
tissue. Control and experimental cells were then stained with PI
and analyzed by flow cytometry.
Western blot analysis
Cells (1610
6) were treated with WithaD (0–4 mM) for 15 hr and
lysate were prepared by sonication (2 watt, 3 pulse). Equal amount
of protein were electrophoresed on SDS-PAGE (10–15%) and
electro-transferred to nitrocellulose membranes. The membrane
was blocked by TBS-BSA, probed with primary antibody
overnight at 4uC, washed with TBS containing 0.1% Tween-20
and incubated with the appropriate HRP-conjugated secondary
antibody. Immunoreactive proteins were detected on X-ray films
using the enhanced chemiluminescence system (Pierce, USA). For
the detection of Bak oligomer, equal amount of mitochondrial
fraction was boiled in sample buffer (-b-Me) and run on 12% SDS-
PAGE and processed [37].
Apoptosis assay
Cells (1610
6) were treated with WithaD (0–6 mM). Phosphati-
dyl-serine externalization was analyzed by double staining the cells
with FITC-annexin V and PI (5 mg/ml) [38]. Alternatively, treated
cells were stained with 7-AAD for 30 minutes. Cells were acquired
and analyzed by CellQuest Pro software (BD FACSCalibur). For
blocking assay, cells were separately pre-treated with caspase 8, 9
and 3 inhibitors IETD-FMK (20 mM), LEHD-FMK (20 mM) and
z-DEVD-CHO (100 mM) respectively for 30 minutes at 37uC
followed by WithaD treatment.
Sub-cellular fractionation
WithaD-treated cells (2610
7) were harvested, washed and
mitochondrial and cytosolic fractions were separated according
to manufacturer’s instructions (Pierce protein research products,
USA). Protein content was measured by Lowry’s method.
Mitochondrial depolarization assay
Mitochondrial transmembrane potential (Dym) was determined
using JC1 by Mitoscreen kit. Briefly, cells (1610
6) were washed
with PBS; JC1 (25 mM) was added and incubated in dark for
15 min at 37uC. Subsequently, they were washed with assay buffer
and acquired immediately by flow cytometer [39].
Statement of Ethics
Animal experiments reported in the manuscript were performed
with the approval of ‘Institutional Animal Ethics Committee’ of
the National Institute of Immunology, New Delhi, India following
the guidelines of CPCSEA. No research on humans has been
carried out.
Statistical analysis
All the results were expressed as the mean 6 S.D. of data
obtained from three separate experiments. All statistical analysis
was evaluated using graph pad prism software (San Diego). Data
were analyzed by the paired t test, and P values less than 0.05 was
considered statistically significant.
Supporting Information
Figure S1 HCT116p53+/+ and HCT116p532/2 cells
were treated with WithaD (0–5 mM) for 24 and 48 hrs and
viabilities were assessed using MTT.
(TIF)
Figure S2 WithaD fails to induce ROS production. (A)
Effect of 1 mM WithaD in different time points (0–2.5 hr) on the
generation of intracellular ROS by H2DCFDA in HCT116 wt
cells. (B) Effect of different doses of WithaD (0–4 mM) after 1 hr on
the generation of intracellular ROS by H2DCFDA in HCT116 wt
cells.
(TIF)
Figure S3 Anti-proliferative effect of WithaD (0–5 mM)
and vehicle treated control for 24 and 48 hr against
cancer cell lines determined by MTT assay.
(TIF)
Figure S4 (A) WithaD (2 mM) treatment for 24 hr induced
morphological changes and detachment of cancer cells from its
substratum. (B) Flow cytometric analysis of annexin-V/PI in
cancer cells treated with WithaD (2 mM) for 24 hr. WithaD
treatment increased the percentage of annexin V
+/PI
2 (down
right quadrant) and annexin V
+/PI
+ (upper right quadrant).
(TIF)
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